Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Fatty Liver D005234 48 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Weight Gain D015430 101 associated lipids
Hyperemia D006940 25 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Bradycardia D001919 13 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Brain Edema D001929 20 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Brain Ischemia D002545 89 associated lipids
Epilepsy D004827 35 associated lipids
Seizures D012640 87 associated lipids
Nerve Degeneration D009410 53 associated lipids
Peptic Ulcer D010437 19 associated lipids
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Hepatitis D006505 11 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Fever D005334 35 associated lipids
Bronchial Spasm D001986 18 associated lipids
Morphine Dependence D009021 9 associated lipids
Shock, Septic D012772 11 associated lipids
Cough D003371 19 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Catalepsy D002375 30 associated lipids
Migraine Disorders D008881 11 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Learning Disorders D007859 11 associated lipids
Hyperkinesis D006948 11 associated lipids
Hyperinsulinism D006946 27 associated lipids
Muscle Spasticity D009128 5 associated lipids
Hypothermia D007035 19 associated lipids
Celiac Disease D002446 16 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hypertension, Portal D006975 12 associated lipids
Insulin Resistance D007333 99 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Brain Concussion D001924 5 associated lipids
Endotoxemia D019446 27 associated lipids
Anorexia D000855 8 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Overweight D050177 11 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neuralgia D009437 28 associated lipids
Fibromyalgia D005356 4 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Bulimia D002032 3 associated lipids
Sleep Deprivation D012892 5 associated lipids
Urinary Incontinence D014549 4 associated lipids
Vascular System Injuries D057772 2 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Ocular Hypotension D015814 2 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Mennella I et al. Food Liking Enhances the Plasma Response of 2-Arachidonoylglycerol and of Pancreatic Polypeptide upon Modified Sham Feeding in Humans. 2015 J. Nutr. pmid:26180248
Palermo G et al. Keys to Lipid Selection in Fatty Acid Amide Hydrolase Catalysis: Structural Flexibility, Gating Residues and Multiple Binding Pockets. 2015 PLoS Comput. Biol. pmid:26111155
Malek N et al. Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. 2015 Neural Plast. pmid:26090232
Qin M et al. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome. 2015 Behav. Brain Res. pmid:25979787
Krishnan G and Chatterjee N Differential immune mechanism to HIV-1 Tat variants and its regulation by AEA [corrected]. 2015 Sci Rep pmid:25943894
Turcotte C et al. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. 2015 J. Leukoc. Biol. pmid:25877930
Spaziano G et al. Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS. 2015 Biomed Res Int pmid:25866824
Subbanna S et al. Postnatal ethanol exposure alters levels of 2-arachidonylglycerol-metabolizing enzymes and pharmacological inhibition of monoacylglycerol lipase does not cause neurodegeneration in neonatal mice. 2015 J. Neurochem. pmid:25857698
Woolcott OO et al. High-fat diet-induced insulin resistance does not increase plasma anandamide levels or potentiate anandamide insulinotropic effect in isolated canine islets. 2015 PLoS ONE pmid:25855974
Nicholson J et al. Leptin levels are negatively correlated with 2-arachidonoylglycerol in the cerebrospinal fluid of patients with osteoarthritis. 2015 PLoS ONE pmid:25835291
Patsenker E et al. Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. 2015 Int J Mol Sci pmid:25826533
Gray JM et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. 2015 J. Neurosci. pmid:25740517
Walentiny DM et al. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. 2015 Neuropharmacology pmid:25698527
Qi M et al. A robust capillary liquid chromatography/tandem mass spectrometry method for quantitation of neuromodulatory endocannabinoids. 2015 Rapid Commun. Mass Spectrom. pmid:26411510
Cascio MG and Marini P Biosynthesis and Fate of Endocannabinoids. 2015 Handb Exp Pharmacol pmid:26408157
Piyanova A et al. Age-related changes in the endocannabinoid system in the mouse hippocampus. 2015 Mech. Ageing Dev. pmid:26278494
Llorente-Berzal A et al. 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. 2015 Psychopharmacology (Berl.) pmid:25814137
Pisanti S et al. Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration. 2015 J. Cell. Physiol. pmid:25684344
Aliczki M et al. Involvement of 2-arachidonoylglycerol signaling in social challenge responding of male CD1 mice. 2015 Psychopharmacology (Berl.) pmid:25547462
Urquhart P et al. Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. 2015 Biochim. Biophys. Acta pmid:25543004
Ford GK et al. Involvement of the endocannabinoid system in attentional modulation of nociceptive behaviour in rats. 2015 Eur J Pain pmid:25504741
Grzeda E et al. Bi-directional CB1 receptor-mediated cardiovascular effects of cannabinoids in anaesthetized rats: role of the paraventricular nucleus. 2015 J. Physiol. Pharmacol. pmid:26084216
Park SW et al. Anticancer effects of anandamide on head and neck squamous cell carcinoma cells via the production of receptor-independent reactive oxygen species. 2015 Head Neck pmid:24797795
Almada M et al. Anandamide and decidual remodelling: COX-2 oxidative metabolism as a key regulator. 2015 Biochim. Biophys. Acta pmid:26335727
Vilela LR et al. Enhancement of endocannabinoid signaling protects against cocaine-induced neurotoxicity. 2015 Toxicol. Appl. Pharmacol. pmid:25933444
Rapino C et al. Endocannabinoids as biomarkers of human reproduction. 2014 Jul-Aug Hum. Reprod. Update pmid:24516083
Thieme U et al. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans. 2014 Jan-Feb Drug Test Anal pmid:24424856
Battista N et al. Analytical approaches for the determination of phytocannabinoids and endocannabinoids in human matrices. 2014 Jan-Feb Drug Test Anal pmid:24218186
Smaga I et al. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. 2014 Neurotox Res pmid:24652522
Chauvet C et al. Chronic stimulation of the tone of endogenous anandamide reduces cue- and stress-induced relapse in rats. 2014 Int. J. Neuropsychopharmacol. pmid:25522382
Morena M et al. Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:25489086
Khasabova IA et al. JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy. 2014 Pharmacol. Res. pmid:25304184
Morty RE and Kuebler WM TRPV4: an exciting new target to promote alveolocapillary barrier function. 2014 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:25281637
McDougle DR et al. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. 2014 J. Pharmacol. Exp. Ther. pmid:25277139
Malek N et al. Alterations in the anandamide metabolism in the development of neuropathic pain. 2014 Biomed Res Int pmid:25276812
De Angelis V et al. Endocannabinoids control platelet activation and limit aggregate formation under flow. 2014 PLoS ONE pmid:25264625
Özdemir B et al. Endocannabinoids and inflammatory response in periodontal ligament cells. 2014 PLoS ONE pmid:25226300
Jia J et al. Anandamide protects HT22 cells exposed to hydrogen peroxide by inhibiting CB1 receptor-mediated type 2 NADPH oxidase. 2014 Oxid Med Cell Longev pmid:25136404
Sexton M et al. Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. 2014 Inflammopharmacology pmid:25135301
Björklund E et al. Involvement of fatty acid amide hydrolase and fatty acid binding protein 5 in the uptake of anandamide by cell lines with different levels of fatty acid amide hydrolase expression: a pharmacological study. 2014 PLoS ONE pmid:25078278
Lau BK et al. Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey. 2014 Br. J. Pharmacol. pmid:25041240
Laprairie RB et al. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. 2014 J. Biol. Chem. pmid:25037227
Cipriano M et al. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. 2014 BMC Res Notes pmid:25012825
Bluett RJ et al. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. 2014 Transl Psychiatry pmid:25004388
Dong W et al. Simulation of Swanson's literature-based discovery: anandamide treatment inhibits growth of gastric cancer cells in vitro and in silico. 2014 PLoS ONE pmid:24949851
Pietrzak RH et al. Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. 2014 Neuropsychopharmacology pmid:24820537
Ravi J et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. 2014 Oncotarget pmid:24811863
Hama AT et al. Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain. 2014 PLoS ONE pmid:24788435
Navarria A et al. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. 2014 Pharmacol. Res. pmid:24861565
Al Kury LT et al. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. 2014 Br. J. Pharmacol. pmid:24758718
Nader J et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. 2014 Neuropharmacology pmid:24709540
Kaczocha M et al. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. 2014 PLoS ONE pmid:24705380
Sun LJ et al. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. 2014 Int. J. Infect. Dis. pmid:24704332
Jackson AR et al. Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. 2014 PLoS ONE pmid:24699635
Baranowska-Kuczko M et al. Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries. 2014 Naunyn Schmiedebergs Arch. Pharmacol. pmid:24682422
Basavarajappa BS et al. Elevation of endogenous anandamide impairs LTP, learning, and memory through CB1 receptor signaling in mice. 2014 Hippocampus pmid:24648181
Engeli S et al. Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects. 2014 Obesity (Silver Spring) pmid:24616451
Gamage TF et al. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. 2014 Behav Pharmacol pmid:24603340
Kwilasz AJ et al. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats. 2014 Behav Pharmacol pmid:24583930
Carr RL et al. Low level chlorpyrifos exposure increases anandamide accumulation in juvenile rat brain in the absence of brain cholinesterase inhibition. 2014 Neurotoxicology pmid:24373905
Oleson EB et al. Cannabinoid receptor activation shifts temporally engendered patterns of dopamine release. 2014 Neuropsychopharmacology pmid:24345819
Marichal-Cancino BA et al. Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats. 2014 Basic Clin. Pharmacol. Toxicol. pmid:24118786
Leo LM et al. Age-dependent relevance of endogenous 5-lipoxygenase derivatives in anxiety-like behavior in mice. 2014 PLoS ONE pmid:24416334
Abdulnour J et al. Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. 2014 Obesity (Silver Spring) pmid:23616305
Brantl SA et al. Mechanism of platelet activation induced by endocannabinoids in blood and plasma. 2014 Platelets pmid:23789792
Hoyer FF et al. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. 2014 J. Mol. Cell. Cardiol. pmid:24286707
Alvheim AR et al. Dietary linoleic acid elevates the endocannabinoids 2-AG and anandamide and promotes weight gain in mice fed a low fat diet. 2014 Lipids pmid:24081493
Pertwee RG Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. 2014 Proc Nutr Soc pmid:24135210
Burston JJ and Woodhams SG Endocannabinoid system and pain: an introduction. 2014 Proc Nutr Soc pmid:24148358
Desroches J et al. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. 2014 Neuropharmacology pmid:24148808
Lu W et al. Voltage-independent sodium channels emerge for an expression of activity-induced spontaneous spikes in GABAergic neurons. 2014 Mol Brain pmid:24886791
Gómez R et al. Endogenous cannabinoid anandamide impairs cell growth and induces apoptosis in chondrocytes. 2014 J. Orthop. Res. pmid:24902823
Kono M et al. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors. 2014 Bioorg. Med. Chem. pmid:24440478
Yang K et al. Differential regulation of NMDAR and NMDAR-mediated metaplasticity by anandamide and 2-AG in the hippocampus. 2014 Hippocampus pmid:25087967
Fezza F et al. Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. 2014 Mol. Cell. Neurosci. pmid:25064144
Pulgar VM et al. Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis. 2014 Hypertension pmid:24935942
Luce V et al. The inhibitory effect of anandamide on oxytocin and vasopressin secretion from neurohypophysis is mediated by nitric oxide. 2014 Regul. Pept. pmid:24342802
Jergas B et al. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus. 2014 Naunyn Schmiedebergs Arch. Pharmacol. pmid:24853577
Pava MJ et al. Endocannabinoid modulation of cortical up-states and NREM sleep. 2014 PLoS ONE pmid:24520411
Sanson B et al. Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. 2014 Acta Crystallogr. D Biol. Crystallogr. pmid:24531463
Ohno-Shosaku T and Kano M Endocannabinoid-mediated retrograde modulation of synaptic transmission. 2014 Curr. Opin. Neurobiol. pmid:24747340
Fowler CJ Has FLAT fallen flat? 2014 Trends Pharmacol. Sci. pmid:24398120
Sousa-Valente J et al. Anandamide in primary sensory neurons: too much of a good thing? 2014 Eur. J. Neurosci. pmid:24494681
Chianese R et al. Hypothalamus-pituitary axis: an obligatory target for endocannabinoids to inhibit steroidogenesis in frog testis. 2014 Gen. Comp. Endocrinol. pmid:24566122
Rea K et al. Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. 2014 Eur. J. Neurosci. pmid:24494683
Zheng Y et al. Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system. 2014 Eur. J. Pharmacol. pmid:24508383
Al Kury LT et al. Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes. 2014 Cell Calcium pmid:24472666
Krishnan G and Chatterjee N Endocannabinoids affect innate immunity of Muller glia during HIV-1 Tat cytotoxicity. 2014 Mol. Cell. Neurosci. pmid:24418364
Björklund E et al. Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. 2014 PLoS ONE pmid:24466356
Nicolussi S et al. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. 2014 Pharmacol. Res. pmid:24412246
Bystrowska B et al. Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training. 2014 Prog. Neuropsychopharmacol. Biol. Psychiatry pmid:24334211
Schaefer C et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. 2014 Eur Arch Psychiatry Clin Neurosci pmid:24253425
Mahavadi S et al. Inhibitory signaling by CB1 receptors in smooth muscle mediated by GRK5/β-arrestin activation of ERK1/2 and Src kinase. 2014 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:24407588
Limebeer CL et al. Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system. 2014 Psychopharmacology (Berl.) pmid:24043345
Jackson AR et al. Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. 2014 J. Leukoc. Biol. pmid:24319288
Okura D et al. The endocannabinoid anandamide inhibits voltage-gated sodium channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus oocytes. 2014 Anesth. Analg. pmid:24557103
Harvey BS et al. Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. 2014 Cytokine pmid:24238999
Piomelli D More surprises lying ahead. The endocannabinoids keep us guessing. 2014 Neuropharmacology pmid:23954677
Alpár A et al. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. 2014 Nat Commun pmid:25030704
Manna JD et al. Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells. 2014 J. Biol. Chem. pmid:25301951